Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab

Background: Bevacizumab, a vascular endothelial growth factor (VEGF) monoclonal antibody commonly used for the treatment of various cancers, is often associated with adverse cardiovascular effects such as hypertension, cardiac and cerebral ischemia, thrombosis, and bleeding events. Factors associate...

Descripción completa

Detalles Bibliográficos
Autores principales: Ngo, Doan T. M., Williams, Trent, Horder, Sophie, Kritharides, Leonard, Vardy, Janette, Mandaliya, Hiren, Nordman, Ina I. C., Lynam, James, Bonaventura, Tony, Sverdlov, Aaron L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465018/
https://www.ncbi.nlm.nih.gov/pubmed/32824667
http://dx.doi.org/10.3390/jcm9082664

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465018/
https://www.ncbi.nlm.nih.gov/pubmed/32824667
http://dx.doi.org/10.3390/jcm9082664

Ejemplares similares